Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?

Biology (Basel) · 2020 · PMC7600176 · PMID 33036377

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The PFS was not significantly different among the 1G or 2G EGFR -TKIs but showed a trend favoring the afatinib group in patients with uncommon EGFR mutation-positive NSCLC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.